CT-guided radiofrequency ablation with chemotherapy in a rabbit VX2 lung tumor model
Project/Area Number |
25461887
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Radiation science
|
Research Institution | Osaka City University |
Principal Investigator |
Okuma Tomohisa 大阪市立大学, 大学院医学研究科, 講師 (50445029)
|
Research Collaborator |
HAMAMOTO Shinichi 大阪市立大学, 大学院医学研究科, 講師 (80711788)
UEKI Ai 大阪市立大学, 大学院医学研究科, 後期臨床研究医 (30551155)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
Keywords | ラジオ波凝固療法 / 癌 / ラジオ波治療 |
Outline of Final Research Achievements |
The results of the present study show that the combination of radiofrequency ablation (RFA) and cisplatin (CDDP)/paclitaxel (PTX) treatment had a significant survival benefit compared to control (without treatment), CDDP/PTX alone or RFA treatment alone in a rabbit lung cancer model with a VX2 tumor. In contrast, treatment with a combination of RFA and CDDP/vinorelbine (VNR) or CDDP/pemetrexed (MTA) chemotherapy did not show any survival benefit compared to the control or the platinum doublet alone chemotherapy and resulted in significantly shorter survival compared to RFA treatment alone. The combination of RFA and systemic platinum-doublet chemotherapy with cisplatin/paclitaxel may improve the local control rate and prolong survival.
|
Report
(4 results)
Research Products
(11 results)